Sangamo Therapeutics clinical trials
Also known as Sangamo BioSciences.
The registry lists 29 studies whose lead sponsor is Sangamo Therapeutics or the company grouped under it. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 3, 2026.
Our grouping of 2 registry names, not the registry’s. See them and correct one ↓
- 29studies on the registry
- 0open to participants now
What it is testing
The drugs Sangamo Therapeutics’ studies test, most studies first; none is open now — 4 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
What changed recently
From the registry's own updates since Oct 19, 2026.
Stopped1
- Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)SuspendedNov 3, 2026NCT06980948
All 29 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 07
- 308
- 09
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 5 started before 2007. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Sangamo Therapeutics.
- Sangamo Therapeutics28 studiesSame company
Something wrong?
- 1 study →
Studies
Recruiting first, then most recently updated. Showing 29 of 29.
- Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)SuspendedNCT06980948Phase 1/2
- Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)CompletedNCT04046224Phase 1/2
- Long-Term Follow-up of Subjects Who Were Treated With ST-920Active, not recruitingNCT05039866
- Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIXTerminatedNCT04628871
- Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant RecipientsCompletedNCT04817774Phase 1/2
- Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)Active, not recruitingNCT05987527
- Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.Active, not recruitingNCT05145062
- A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell DiseaseCompletedNCT03653247Phase 1/2
- Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia BTerminatedNCT02695160Phase 1
- Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-TTerminatedNCT04201782
- A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)CompletedNCT03432364Phase 1/2
- Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS ITerminatedNCT02702115Phase 1/2
- CERE-110 in Subjects With Mild to Moderate Alzheimer's DiseaseCompletedNCT00087789Phase 1
- Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's DiseaseCompletedNCT00252850Phase 1
- Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's DiseaseCompletedNCT00400634Phase 2
- Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS IITerminatedNCT03041324Phase 1/2
- Clinical Trial of SB-509 in Subjects With Diabetic NeuropathyCompletedNCT01079325Phase 2
- Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-TCompletedNCT01543152Phase 1/2
- Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAARTCompletedNCT02225665Phase 1/2
- Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's DiseaseCompletedNCT00876863Phase 2
- Safety and Efficacy of CERE-120 in Subjects With Parkinson's DiseaseCompletedNCT00985517Phase 1/2
- Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected SubjectsCompletedNCT01252641Phase 1/2
- Study Evaluating Ovasave, an Autologous Cell Therapy, in Patients With Active Crohn's DiseaseTerminatedNCT02327221Phase 2
Sponsor listed in the registry: TxCell · First submitted before TxCell became part of Sangamo Therapeutics
- Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected PatientsCompletedNCT01044654Phase 1
- Clinical Trial of SB-509 in Subjects With Diabetic NeuropathyCompletedNCT00476931Phase 2
- Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00748501Phase 2
- Clinical Trial of SB-509 in Subjects With Diabetic NeuropathyCompletedNCT00406458Phase 2
- Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509CompletedNCT00665145Phase 2
- Clinical Trial of SB-509-0401 in Subjects With Diabetic NeuropathyCompletedNCT00110500Phase 1